Drug Type Antibody drug conjugate (ADC) |
Synonyms DM 005, DM-005, DM005 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | - | 01 Sep 2024 | |
Non-Small Cell Lung Cancer | Phase 1 | - | 01 Sep 2024 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | 01 Sep 2024 | |
Solid tumor | IND Approval | US | 29 Aug 2024 | |
Pancreatic Ductal Adenocarcinoma | Preclinical | CN | 02 Nov 2023 |